After initiating Kerentia (finerenone), which laboratory tests need to be checked and at what frequency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Laboratory Monitoring After Starting Kerendia (Finerenone)

Check serum potassium at 1 month after initiation, then every 4 months during ongoing treatment. 1

Initial Monitoring Protocol

The KDIGO 2024 guidelines provide explicit monitoring recommendations for finerenone:

  • At 1 month post-initiation: Check serum potassium
  • Every 4 months thereafter: Continue regular potassium monitoring during maintenance therapy

This monitoring schedule applies regardless of whether you're maintaining the initial dose or uptitrating from 10 mg to 20 mg daily. 1

Potassium-Based Management Algorithm

The monitoring isn't just about checking labs—it's about acting on the results:

If K+ ≤4.8 mmol/L (≤4.8 mEq/L):

  • Continue finerenone at current dose (10 mg or 20 mg)
  • If patient is on 10 mg daily, uptitrate to 20 mg daily
  • Continue monitoring every 4 months

If K+ 4.9-5.5 mmol/L:

  • Continue finerenone at current dose
  • Do not uptitrate if on 10 mg
  • Monitor potassium every 4 months

If K+ >5.5 mmol/L:

  • Hold finerenone immediately
  • Address hyperkalemia through dietary modifications or adjustment of concomitant medications
  • Recheck potassium
  • Restart at 10 mg daily when K+ ≤5.0 mmol/L 1, 2

Additional Laboratory Considerations

While potassium is the primary lab requiring specific monitoring intervals, you should also track:

  • eGFR: Continue routine CKD monitoring per your usual schedule (typically every 3-12 months depending on CKD stage). Finerenone initiation does not necessitate more frequent eGFR monitoring. 1

  • UACR (urine albumin-to-creatinine ratio): Monitor as part of standard CKD care to assess treatment response, though no specific finerenone-related monitoring interval is mandated by guidelines.

Critical Pitfalls to Avoid

Don't discontinue finerenone for mild potassium elevations. The 4.9-5.5 mmol/L range is a "continue and monitor" zone, not a discontinuation threshold. Only hold the medication when potassium exceeds 5.5 mmol/L. 1

Don't forget the 1-month check. This is when hyperkalemia is most likely to manifest. Real-world data shows hyperkalemia occurs in approximately 8-10% of patients, but severe cases requiring hospitalization are rare (0.3%). 3, 4

Don't assume you need to check potassium more frequently than every 4 months after the initial month unless clinical circumstances change (e.g., acute illness, addition of other potassium-affecting medications, or development of hyperkalemia).

Real-World Context

Recent real-world studies confirm that this monitoring schedule is practical and safe. In the FINE-REAL study of nearly 2,000 patients, hyperkalaemia occurred in 8% of participants but led to discontinuation in only 1% and hospitalization in 0.3%, with no fatal cases. 3 The FOUNTAIN platform study showed even lower rates with hyperkalemia occurring in just 1.2% of patients at 12 months. 5

The bottom line: Potassium at 1 month, then every 4 months. This simple schedule, combined with the action thresholds above, allows safe and effective use of finerenone while minimizing the risk of clinically significant hyperkalemia.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.